| Product Code: ETC7199659 | Publication Date: Sep 2024 | Updated Date: Nov 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Vasudha | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
In 2024, Finland continued to heavily rely on imports of insulin biosimilars, with leading exporters being the USA, Germany, UK, Austria, and New Zealand. The market concentration, as measured by the Herfindahl-Hirschman Index (HHI), remained very high, indicating a dominant market presence of these top exporting countries. Despite a notable compound annual growth rate (CAGR) of 24.17% from 2020 to 2024, there was a decline in growth rate from 2023 to 2024 at -20.18%, suggesting a potential slowdown in the market. Stakeholders should closely monitor these trends for strategic decision-making.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Finland Insulin Biosimilars Market Overview |
3.1 Finland Country Macro Economic Indicators |
3.2 Finland Insulin Biosimilars Market Revenues & Volume, 2021 & 2031F |
3.3 Finland Insulin Biosimilars Market - Industry Life Cycle |
3.4 Finland Insulin Biosimilars Market - Porter's Five Forces |
3.5 Finland Insulin Biosimilars Market Revenues & Volume Share, By Product Type, 2021 & 2031F |
3.6 Finland Insulin Biosimilars Market Revenues & Volume Share, By Indicative, 2021 & 2031F |
3.7 Finland Insulin Biosimilars Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Finland Insulin Biosimilars Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Finland Insulin Biosimilars Market Trends |
6 Finland Insulin Biosimilars Market, By Types |
6.1 Finland Insulin Biosimilars Market, By Product Type |
6.1.1 Overview and Analysis |
6.1.2 Finland Insulin Biosimilars Market Revenues & Volume, By Product Type, 2021- 2031F |
6.1.3 Finland Insulin Biosimilars Market Revenues & Volume, By Rapid-acting biosimilar, 2021- 2031F |
6.1.4 Finland Insulin Biosimilars Market Revenues & Volume, By Long-acting biosimilar, 2021- 2031F |
6.1.5 Finland Insulin Biosimilars Market Revenues & Volume, By Premixed biosimilar, 2021- 2031F |
6.2 Finland Insulin Biosimilars Market, By Indicative |
6.2.1 Overview and Analysis |
6.2.2 Finland Insulin Biosimilars Market Revenues & Volume, By Type I Diabetes, 2021- 2031F |
6.2.3 Finland Insulin Biosimilars Market Revenues & Volume, By Type II Diabetes, 2021- 2031F |
6.3 Finland Insulin Biosimilars Market, By End User |
6.3.1 Overview and Analysis |
6.3.2 Finland Insulin Biosimilars Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.3.3 Finland Insulin Biosimilars Market Revenues & Volume, By Ambulatory Surgical Centers, 2021- 2031F |
6.3.4 Finland Insulin Biosimilars Market Revenues & Volume, By Others, 2021- 2031F |
7 Finland Insulin Biosimilars Market Import-Export Trade Statistics |
7.1 Finland Insulin Biosimilars Market Export to Major Countries |
7.2 Finland Insulin Biosimilars Market Imports from Major Countries |
8 Finland Insulin Biosimilars Market Key Performance Indicators |
9 Finland Insulin Biosimilars Market - Opportunity Assessment |
9.1 Finland Insulin Biosimilars Market Opportunity Assessment, By Product Type, 2021 & 2031F |
9.2 Finland Insulin Biosimilars Market Opportunity Assessment, By Indicative, 2021 & 2031F |
9.3 Finland Insulin Biosimilars Market Opportunity Assessment, By End User, 2021 & 2031F |
10 Finland Insulin Biosimilars Market - Competitive Landscape |
10.1 Finland Insulin Biosimilars Market Revenue Share, By Companies, 2024 |
10.2 Finland Insulin Biosimilars Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |